Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Are different types of BCR-ABL1 transcripts associated with different outcomes?

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study examined outcomes in chronic myeloid leukemia (CML) patients with different types of a genetic abnormality known as BCR-ABL1. While patients with the BCR-ABL transcript e14a2 showed better response to treatment, long-term outcomes were similar between groups. Some background Certain genetic changes in CML can make it more...

Read More

Antithymocyte globulin before transplantation for patients with acute myeloid leukemia

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to analyze the impact of antithymocyte globulin doses in patients with acute myeloid leukemia in first complete remission undergoing transplantation. This study concluded that an antithymocyte globulin dose less than 6mg/kg is enough to prevent graft versus host disease. Doses higher than this impair disease control and...

Read More

What effect do different stem cell types have in transplantation for patients with acute leukemia?

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effect of stem cell source on haploidentical transplantation with post-transplantation cyclophosphamide (a chemotherapy) in patients with acute leukemia. This study concluded that the use of peripheral blood stem cells increases the risk of side effects for these patients. Some background Patients...

Read More

Comparing treatment regimens in patients with relapsed or refractory acute myeloid leukemia

Posted by on Feb 15, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to compare myeloablative transplant and a sequential approach treatment in patients with relapsed or refractory acute myeloid leukemia. This study concluded that both treatments had similar outcomes for these patients.  Some background Allogeneic hematopoietic stem cell transplantation (HSCT) is the only...

Read More

An overview of the dose management of dasatinib

Posted by on Feb 5, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...

Read More

Combined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?

Posted by on Jan 30, 2018 in Leukemia | 0 comments

In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...

Read More

To Treat or Not To Treat Cancer: Medical Decision-making

To Treat or Not To Treat Cancer: Medical Decision-making

Posted by on Jan 28, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma | 3 comments

Cherry Hughes** is an active, energetic 75 year old, still working in the marketing and public relations profession in Great Britain.  Her life is filled with friends and fun.  “I love cooking and eating out.  I am deeply interested in politics.  I love music …I go to jazz clubs.  I love going to France …I have a little apartment...

Read More

Chromosomal abnormalities at diagnosis does not predict long-term treatment outcomes with tyrosine kinase inhibitors

Posted by on Jan 28, 2018 in Leukemia | 0 comments

In a nutshell This study examined whether chromosomal abnormalities at diagnosis can predict treatment outcomes with TKIs in chronic myeloid leukemia (CML). Researchers reported similar long-term treatment outcomes in patients with and without chromosomal abnormalities at diagnosis. Some background CML is a disease in which the bone marrow makes...

Read More

A review of CAR-T cell therapy for CLL

Posted by on Jan 27, 2018 in Leukemia | 0 comments

In a nutshell This study reviewed CAR-T cell therapy, a new type of immunotherapy, for chronic lymphocytic leukemia (CLL). Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In this treatment, immune cells (the T-cells) are removed from the blood. The T-cells are then genetically modified...

Read More

Getting off the drugs: Tapering immunosuppressive agents after transplant in patients with advanced acute myeloid leukemia

Posted by on Jan 27, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effect of early tapering of immunosuppressive agents after stem cell transplants in patients with acute myeloid leukemia. This study concluded that early tapering of immunosuppressive agents after stem fell transplants in these patients can improve survival. Some background Allogeneic...

Read More

Can BMI impact outcomes of children with acute leukemia who undergo a transplant?

Posted by on Jan 24, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if body mass index can impact outcomes of children with acute leukemia undergoing stem cell transplantation. This study concluded that being underweight at the time of transplant is associated with an increased risk of acute graft versus host disease in these patients.  Some background Body mass...

Read More